Fractyl Health, Inc. (NASDAQ:GUTS) Insider Jay David Caplan Sells 64,197 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 64,197 shares of Fractyl Health stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $158,566.59. Following the sale, the insider now owns 153,544 shares in the company, valued at approximately $379,253.68. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jay David Caplan also recently made the following trade(s):

• On Thursday, September 12th, Jay David Caplan sold 65,000 shares of Fractyl Health stock. The shares were sold at an average price of $2.90, for a total transaction of $188,500.00.

Fractyl Health Stock Performance

Shares of Fractyl Health stock opened at $2.37 on Thursday. The stock has a market cap of $113.59 million and a price-to-earnings ratio of -0.19. The company has a quick ratio of 7.46, a current ratio of 7.46 and a debt-to-equity ratio of 0.40. Fractyl Health, Inc. has a twelve month low of $1.74 and a twelve month high of $14.50. The company’s fifty day moving average is $2.63 and its 200 day moving average is $4.05.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. Sell-side analysts forecast that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently modified their holdings of the company. American International Group Inc. bought a new position in Fractyl Health during the first quarter worth $9,911,000. SG Americas Securities LLC bought a new position in shares of Fractyl Health in the 3rd quarter worth about $33,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Fractyl Health by 2.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock valued at $4,255,000 after purchasing an additional 25,829 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Fractyl Health in the 2nd quarter valued at about $61,000. Finally, Rhumbline Advisers bought a new stake in shares of Fractyl Health during the 2nd quarter valued at about $32,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.